Abliva’s NV354 to progress to clinical development

20 September, 2021Biopharma company Abliva ended last week on a high note when it announced positive feedback from the MHRA, the UK regulatory authority, regarding its program NV354. The feedback concerns the preclinical package compiled on NV354 and means that the candidate can now progress to clinical development. Abliva aims to initiate a phase I … Continue reading Abliva’s NV354 to progress to clinical development